NCT05887609 2025-10-30
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
Phase 2 Recruiting
Clinical Trials
6 trialsNCT04606914 2025-09-08
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
University of Alabama at Birmingham
Phase 2 Recruiting
NCT03832361 2025-07-18
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
Yale University
Phase 2 Recruiting
NCT03835819 2025-05-15
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03106077 2020-12-02
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03836157 2019-06-27
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
University of Oklahoma
Phase 2 Withdrawn